Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Item 9 Labs (INLB) Cash & Equivalents (2016 - 2023)

Item 9 Labs' Cash & Equivalents history spans 13 years, with the latest figure at $183429.0 for Q2 2023.

  • For Q2 2023, Cash & Equivalents fell 58.47% year-over-year to $183429.0; the TTM value through Jun 2023 reached $183429.0, down 58.47%, while the annual FY2022 figure was $85637.0, 94.11% down from the prior year.
  • Cash & Equivalents reached $183429.0 in Q2 2023 per INLB's latest filing, up from $101150.0 in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $4.3 million in Q1 2021 to a low of $21781.0 in Q4 2022.
  • Average Cash & Equivalents over 5 years is $838226.6, with a median of $441662.0 recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: soared 1617.66% in 2021, then tumbled 97.56% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $564344.0 in 2019, then skyrocketed by 185.92% to $1.6 million in 2020, then plummeted by 90.04% to $160711.0 in 2021, then plummeted by 86.45% to $21781.0 in 2022, then skyrocketed by 742.15% to $183429.0 in 2023.
  • Per Business Quant, the three most recent readings for INLB's Cash & Equivalents are $183429.0 (Q2 2023), $101150.0 (Q1 2023), and $21781.0 (Q4 2022).